Cancer rankings data visualisation
The cancer rankings data visualisation provides the top 20 cancers diagnosed between 1982 and 2023. The visualisation also includes the leading 20 cancers causing death between 2007 and 2023. The rankings are available by sex and age group (including all ages) and can be presented as counts or rates. Age–standardised rates are standardised to the 2023 Australian population but the equivalent rates standardised to the 2001 Australian Standard Population are available in the cancer incidence and cancer mortality, by age visualisations.
Help with terms, and information about the data, is available by placing the mouse pointer over the icons found near the top of the page.
This visualisation contains tabulated rankings of the top 20 cancers most commonly diagnosed from 1982 to the most recent year available for reporting at the time of release. Data is available for all ages combined and by 20-year age groups from 0–19, 20–39, 40–59, 60–79 and 80 and over.

ABS (Australian Bureau of Statistics) 2018. Population projections, Australia, 2017 (base) – 2066. ABS cat. no. 3222.0. Canberra: ABS.
AIHW (Australian Institute of Health and Welfare) 2019. BreastScreen Australia monitoring report 2018. Cancer series no.127. Cat no. CAN128. Canberra: AIHW
Al-Marhoon M, Osman A, Kamal M and Shokier A 2011. Incidental vs symptomatic renal tumours: Survival outcomes. Arab Journal of Urology 9(1): 17–21.
Brenner H and Gefeller O 1996. An alternative approach to monitoring cancer patient survival. Cancer78:2004–10.
Dickman PW 2004. Estimating and modelling relative survival using SAS. Stockholm: Karolinska Institutet. Viewed 26 May 2020.
Ederer F & Heise H 1959. Instructions to IBM 650 programmers in processing survival computations. Methodological note.
Greenwood M 1926. The errors of sampling of the survivorship table. Reports on public health and medical subjects. Vol 33. London: Her Majesty’s Stationery Office.
Jensen O, Parkin D, MacLennan R, Muir C & Skeet R (eds) 1991. Cancer registration: principles and methods. IARC scientific publications no. 95. Lyon: IARC.
Luke C, Tracey E, Stapleton A and Roder D 2010. Exploring contrary trends in bladder cancer incidence, mortality and survival: implications for cancer research and cancer control. Internal Medicine Journal 40:357–62.
Qaseem A, Usman N, Jayaraj J S, et al. (September 02, 2019) Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site. Cureus 11(9): e5552. doi:10.7759/cureus.5552
Skuladottir H & Olsen JH 2003. Conditional survival of patients with the four major histologic subgroups of lung cancer in Denmark. Journal of Clinical Oncology 21(16):3035–40.
Smith D Supramaniam R, Marshall V and Armstrong B 2008. Prostate cancer and prostate specific antigen testing in New South Wales. Medical Journal of Australia 189(6): 315–18.
Vaccarella S, Franceschi S, Bray F, Wild C, Plummer M and Dal Maso L 2016. The increase in thyroid cancer may be due to an increase in medical surveillance and the introduction of new diagnostic techniques, such as neck ultrasonography. The New England Journal of Medicine 375: 614–17.